TESARO (NASDAQ:TSRO) saw its share price trade relatively negative in the recent trading session. The share price was last updated to $40.92 with a loss of -1.52 points or -3.58%. The net money flow was $2.38 million and the up/down ratio was 1.73. Approximately $5.63 million was the inflow in upticks and $3.25 million was the outflow in downticks. On a weekly measure, the shares have seen a price change of -0.9%.The shares witnessed a block transaction with a net money flow of $2.45 million. The total money in uptick was $2.45 million and in downtick was $0 million with the up/down ratio reaching 0.
The stock has recorded a 20-day Moving Average of 6.73% and the 50-Day Moving Average is 5.66%. The company shares have dropped 29.2% in the past 52 Weeks. On July 20, 2015 The shares registered one year high of $66.95 and one year low was seen on February 9, 2016 at $29.51. The 50-day moving average is $43.05 and the 200 day moving average is recorded at $43.1. S&P 500 has rallied 1.93% during the last 52-weeks.
TESARO (NASDAQ:TSRO): The stock opened at $42.40 on Tuesday but the bulls could not build on the opening and the stock topped out at $42.45 for the day. The stock traded down to $40.76 during the day, due to lack of any buying support eventually closed down at $40.94 with a loss of -3.53% for the day. The stock had closed at $42.44 on the previous day. The total traded volume was 570,586 shares.
Currently the company Insiders own 40.5% of TESARO shares according to the proxy statements. During last six month period, the net percent change held by insiders has seen a change of 8.02%. On the companys insider trading activities,The officer (VP of Finance & Administration) of Tesaro, Inc., English Edward C sold 7,000 shares at $41.21 on June 10, 2016. The Insider selling transaction had a total value worth of $288,470. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.